Clinical Trials Browser

Phase 2 × Unknown × Nivolumab × Clear all

NCT06566391 2024-08-22

Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma

Phase 2 Unknown

Melanoma

NCT04062656 2024-03-12

IMAGINE

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05178043 2024-02-22

GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03818685 2024-02-12

BreastImmune03

Phase 2 Unknown

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03146650 2024-01-18

Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer

Phase 2 Unknown

25 enrolled 14 charts

Salivary Gland Neoplasms

NCT05859477 2024-01-02

NIVOFGFR2

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT02977052 2023-11-15

OpACIN-neo

Phase 2 Unknown

Melanoma

NCT03097939 2023-10-11

Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03528408 2023-04-11

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

Phase 2 Unknown

Uveal Melanoma, Melanoma

NCT05772624 2023-03-16

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05660993 2022-12-21

Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT03529890 2022-10-20

RACE IT

Phase 2 Unknown

Urinary Bladder Neoplasms

NCT05588297 2022-10-20

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Phase 2 Unknown

Gastrointestinal

Colorectal Cancer Liver Metastases

NCT04913025 2022-09-21

REFINE

Phase 2 Unknown

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT04575922 2022-09-08

Nivolumab+Ipilimumab+RT in MSS mCRC

Phase 2 Unknown

Gastrointestinal

Metastatic Microsatellite Stable Colorectal Cancer

NCT04525638 2022-08-02

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Phase 2 Unknown

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Phase 2 Unknown

Gastrointestinal

PD-1 Antibody

NCT04013334 2022-06-16

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Phase 2 Unknown

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05385263 2022-05-26

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Phase 2 Unknown

Lymphoma, B-Cell

NCT03808480 2022-04-06

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04876313 2022-04-06

NURE-Combo

Phase 2 Unknown

Muscle-Invasive Bladder Carcinoma

NCT03993249 2022-03-23

Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

Phase 2 Unknown

Urinary Bladder Neoplasms

NCT02499367 2022-03-22

TONIC

Phase 2 Unknown

Breast Neoplasms, Neoplasm Metastasis

NCT05224999 2022-02-04

Nivolumab for Recurrent/Metastatic Carcinosarcoma

Phase 2 Unknown

Carcinosarcoma

NCT03219775 2021-11-03

TITAN-TCC

Phase 2 Unknown

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT03146468 2021-09-23

NIVALLO

Phase 2 Unknown

Other hematologic neoplasm

Hematologic Neoplasms

NCT03040791 2021-08-26

ImmunoProst

Phase 2 Unknown

Prostatic Neoplasms

NCT04761744 2021-02-21

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

Phase 2 Unknown

Neoplasm Metastasis

NCT04134182 2020-12-23

Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.

Phase 2 Unknown

Carcinoma, Renal Cell

NCT03048500 2020-10-14

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2 Unknown

17 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04503967 2020-08-07

OASIS

Phase 2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04377048 2020-05-06

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Phase 2 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT04131621 2020-04-15

CheCUP

Phase 2 Unknown

Neoplasms, Unknown Primary

NCT03823625 2020-03-25

SQUINT

Phase 2 Unknown

Squamous-Cell Lung Cancer

NCT04015778 2020-02-12

A Two-arm (Phase 2) Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04250246 2020-01-31

NIBIT-ML1

Phase 2 Unknown

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04211896 2019-12-26

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04023617 2019-07-17

A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03864575 2019-07-12

NICE-COMBO

Phase 2 Unknown

Neoplasm Metastasis

NCT04017897 2019-07-12

The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma

Phase 2 Unknown

Melanoma

NCT03569696 2019-04-23

NivoM

Phase 2 Unknown

Lymphoma, B-Cell

NCT02852083 2018-01-18

ModuLung

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Phase 2 Unknown

GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor